cbdMD (YCBD) has shared an update. cbdMD, Inc. has made significant leadership and board appointments, including Bradley Whitford as Chief Accounting Officer, Scott Stephen as Chairman of the Board, and
cbdMD (YCBD) has shared an update. cbdMD, Inc. has made significant leadership and board appointments, including Bradley Whitford as Chief Accounting Officer, Scott Stephen as Chairman of the Board, and
cbdMD (YCBD) has provided an update. Starting February 29, 2024, cbdMD, Inc. executives will use an investor presentation during their non-deal road shows, which will also be accessible on the
06:04 EST cbdMD files to sell 5.14M shares of common stock for holders Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Genmab (GMAB – Research Report), cbdMD (YCBD – Research Report) and SAGE Therapeutics (SAGE – Research Report).
Genmab (GMAB)
In a report released today, Kaveri Pohlman from BTIG maintained a Buy rating on Genmab, with a price target of $46.00. The company’s shares closed last Wednesday at $27.59, close to its 52-week low of $26.32.
According to TipRanks.com, Pohlman is a 3-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Genmab with a $40.40 average price target.
See the top stocks recommended by analysts >>
cbdMD (YCBD)
In a report released yesterday, Anthony Vendetti from Maxim Group maintained a Buy rating on cbdMD. The company’s shares closed last Wednesday at $0.64, close to its 52-week low of $0.56.
According to TipRanks.com, Vendetti is a 1-star analyst with an average return of
The the analyst consensus on cbdMD is currently a Moderate Buy rating.
SAGE Therapeutics (SAGE)
Oppenheimer analyst Jay Olson maintained a Hold rating on SAGE Therapeutics today and set a price target of $25.00. The company’s shares closed last Wednesday at $25.75.
According to TipRanks.com, Olson is a 5-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for SAGE Therapeutics with a $25.08 average price target, a -0.7% downside from current levels. In a report released yesterday, Goldman Sachs also maintained a Hold rating on the stock with a $28.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on GMAB:
Cbdmd INc (YCBD) is scheduled to report 1st quarter earnings on 02/13/2024, after the market closes. Regarding Q1 estimates, Wall Street analysts expect Cbdmd INc to post earnings of -$0.74